Cyclosporine Inhalation Solution (CIS)

DRUG3 trials

Sponsors

APT Pharmaceuticals, Inc., National Heart, Lung, and Blood Institute (NHLBI)

Conditions

Bronchiolitis ObliteransBronchiolitis, ExudativeBronchiolitis, ProliferativeConstructive BronchiolitisGraft Versus Host DiseaseGraft-Versus-Host DiseaseLung Transplant

Phase 2

Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans

CompletedNCT01273207

National Heart, Lung, and Blood Institute (NHLBI)Bronchiolitis, Exudative, Bronchiolitis Obliterans, Bronchiolitis, Proliferative +3

Start: 2012-03-02End: 2019-05-23Updated: 2020-09-18

Phase 3

Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation

CompletedNCT00755781

APT Pharmaceuticals, Inc.Lung Transplant

Start: 2008-09-30End: 2011-11-30Updated: 2012-09-17

CIS001 Extension Study of Cyclosporine Inhalation Solution

TerminatedNCT00938236

APT Pharmaceuticals, Inc.Lung Transplant

Start: 2009-12-31End: 2011-12-31Updated: 2012-09-17